

# Diana Ferraro

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9488130/publications.pdf>

Version: 2024-02-01

110  
papers

2,661  
citations

185998

28  
h-index

233125

45  
g-index

113  
all docs

113  
docs citations

113  
times ranked

3232  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 175.                   | 3.8 | 336       |
| 2  | Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. <i>Lancet Neurology</i> , The, 2020, 19, 307-316.   | 4.9 | 219       |
| 3  | DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 1738-1744.  | 1.7 | 86        |
| 4  | Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 458-468.   | 0.9 | 71        |
| 5  | Topiramate in migraine prophylaxis: a randomised double-blind versus placebo study. <i>Neurological Sciences</i> , 2004, 25, 245-250.   | 0.9 | 65        |
| 6  | Topiramate and Triptans Revert Chronic Migraine With Medication Overuse to Episodic Migraine. <i>Clinical Neuropharmacology</i> , 2006, 29, 269-275.  | 0.2 | 64        |
| 7  | Aging with HIV infection: A journey to the center of inflammAIDS, immunosenescence and neuroHIV. <i>Immunology Letters</i> , 2014, 162, 329-333.  | 1.1 | 59        |
| 8  | A quantitative comparison of BOLD fMRI responses to noxious and innocuous stimuli in the human spinal cord. <i>NeuroImage</i> , 2010, 50, 1408-1415.  | 2.1 | 55        |
| 9  | Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. <i>Neurology</i> , 2021, 96, e783-e797.  | 1.5 | 54        |
| 10 | Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome. <i>Journal of Neuroimmunology</i> , 2013, 257, 76-81. | 1.1 | 53        |
| 11 | mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.                              | 0.9 | 53        |
| 12 | Risk of secondary progressive multiple sclerosis: A longitudinal study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 79-90.  | 1.4 | 52        |
| 13 | Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: Association with oligoclonal IgM bands and prediction of Multiple Sclerosis diagnosis. <i>Journal of Neuroimmunology</i> , 2015, 283, 64-69. | 1.1 | 48        |
| 14 | “Better explanations” in multiple sclerosis diagnostic workup. <i>Neurology</i> , 2019, 92, e2527-e2537.  | 1.5 | 44        |
| 15 | Cell-based assays for the detection of MOG antibodies: a comparative study. <i>Journal of Neurology</i> , 2020, 267, 3555-3564.   | 1.8 | 44        |
| 16 | Mechanisms of neuropathic pain in patients with Charcot-Marie-Tooth 1 A: A laser-evoked potential study. <i>Pain</i> , 2010, 149, 379-385.  | 2.0 | 40        |
| 17 | Habituation to Pain in “Medication Overuse Headache”: A CO <sub>2</sub> Laser-Evoked Potential Study. <i>Headache</i> , 2012, 52, 792-807.  | 1.8 | 40        |
| 18 | Systematic assessment and characterization of chronic pain in multiple sclerosis patients. <i>Neurological Sciences</i> , 2018, 39, 445-453.  | 0.9 | 39        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Changing incidence and subtypes of ALS in Modena, Italy: A 10-years prospective study. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2011, 12, 451-457.   | 2.3 | 38        |
| 20 | Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. <i>Neurology</i> , 2017, 89, 1050-1059.  | 1.5 | 38        |
| 21 | Invariant natural killer T cells and mucosal-associated invariant T cells in multiple sclerosis. <i>Immunology Letters</i> , 2017, 183, 1-7.  | 1.1 | 36        |
| 22 | Cladribine versus fingolimod, natalizumab and interferon $\beta$ for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1617-1626.   | 1.4 | 36        |
| 23 | Definitive childlessness in women with multiple sclerosis: a multicenter study. <i>Neurological Sciences</i> , 2017, 38, 1453-1459.   | 0.9 | 35        |
| 24 | Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 28, 235-243.                          | 0.9 | 35        |
| 25 | Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM. <i>Multiple Sclerosis Journal</i> , 2011, 17, 303-311.                                       | 1.4 | 34        |
| 26 | Percutaneous endoscopic gastrostomy, body weight loss and survival in amyotrophic lateral sclerosis: a population-based registry study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2017, 18, 233-242. | 1.1 | 34        |
| 27 | Plasma neurofilaments correlate with disability in progressive multiple sclerosis patients. <i>Acta Neurologica Scandinavica</i> , 2020, 141, 16-21.  | 1.0 | 33        |
| 28 | Early clinical markers of aggressive multiple sclerosis. <i>Brain</i> , 2020, 143, 1400-1413.   | 3.7 | 32        |
| 29 | Topiramate in the prevention of pediatric migraine: literature review. <i>Journal of Headache and Pain</i> , 2008, 9, 147-150.  | 2.5 | 31        |
| 30 | Risk of Getting COVID-19 in People With Multiple Sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2022, 9, .  | 3.1 | 31        |
| 31 | Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 38, 101868.  | 0.9 | 29        |
| 32 | The Abnormal Recovery Cycle of Somatosensory Evoked Potential Components in Children with Migraine can be Reversed by Topiramate. <i>Cephalalgia</i> , 2010, 30, 17-26.   | 1.8 | 27        |
| 33 | iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. <i>Frontiers in Immunology</i> , 2016, 7, 555.   | 2.2 | 27        |
| 34 | Cerebrospinal fluid kappa and lambda free light chains in oligoclonal band-negative patients with suspected multiple sclerosis. <i>European Journal of Neurology</i> , 2020, 27, 461-467.   | 1.7 | 26        |
| 35 | Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2021, 78, 726.   | 4.5 | 26        |
| 36 | Mitochondrial functionality and metabolism in T cells from progressive multiple sclerosis patients. <i>European Journal of Immunology</i> , 2019, 49, 2204-2221.  | 1.6 | 24        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Delay from treatment start to full effect of immunotherapies for multiple sclerosis. <i>Brain</i> , 2020, 143, 2742-2756.  | 3.7 | 24        |
| 38 | Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study. <i>Neurotherapeutics</i> , 2021, 18, 1166-1174.              | 2.1 | 24        |
| 39 | Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy. <i>Journal of the Neurological Sciences</i> , 2018, 391, 72-76.                           | 0.3 | 22        |
| 40 | Amyotrophic lateral sclerosis: a comparison of two staging systems in a population-based study. <i>European Journal of Neurology</i> , 2016, 23, 1426-1432.  | 1.7 | 21        |
| 41 | Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. <i>Journal of Neurology</i> , 2018, 265, 424-430.  | 1.8 | 21        |
| 42 | Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. <i>Frontiers in Neurology</i> , 2019, 10, 916.              | 1.1 | 21        |
| 43 | Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. <i>JAMA Neurology</i> , 2020, 77, 1398.                            | 4.5 | 21        |
| 44 | Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. <i>JAMA Neurology</i> , 2018, 75, 1407.  | 4.5 | 20        |
| 45 | Kappa Index versus CSF Oligoclonal Bands in Predicting Multiple Sclerosis and Infectious/Inflammatory CNS Disorders. <i>Diagnostics</i> , 2020, 10, 856.   | 1.3 | 19        |
| 46 | Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors. <i>Multiple Sclerosis Journal</i> , 2021, 27, 430-438.                                      | 1.4 | 19        |
| 47 | A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. <i>Journal of Neurology</i> , 2017, 264, 973-978.   | 1.8 | 18        |
| 48 | Increased plasma levels of mitochondrial DNA and pro-inflammatory cytokines in patients with progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2020, 338, 577107.                  | 1.1 | 18        |
| 49 | Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study. <i>Current Medical Research and Opinion</i> , 2014, 30, 1849-1855. | 0.9 | 17        |
| 50 | Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS. <i>Neurology: Clinical Practice</i> , 2020, 10, 510-519.                                      | 0.8 | 17        |
| 51 | Occupational head injury and subsequent glioma. <i>Neurological Sciences</i> , 2003, 24, 31-33.  | 0.9 | 15        |
| 52 | Acute necrotizing encephalopathy: a relapsing case in a European adult. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 227-228.  | 0.9 | 15        |
| 53 | Mitochondrial damage-associated molecular patterns stimulate reactive oxygen species production in human microglia. <i>Molecular and Cellular Neurosciences</i> , 2020, 108, 103538.                 | 1.0 | 15        |
| 54 | Efficacy of mechanical thrombectomy in patients with ischemic stroke and cancer. <i>Journal of Clinical Neuroscience</i> , 2021, 91, 20-22.  | 0.8 | 15        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Oligoclonal bands: clinical utility and interpretation cues. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 391-404.  | 2.7 | 15        |
| 56 | Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1864-1873.                                   | 0.7 | 14        |
| 57 | Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101461.                     | 0.9 | 14        |
| 58 | Serum neurofilament light as biomarker of seizure-related neuronal injury in status epilepticus. <i>Epilepsia</i> , 2022, 63, e23.   | 2.6 | 14        |
| 59 | Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. <i>Neurology</i> , 2018, 90, 852-854.  | 1.5 | 13        |
| 60 | First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence. <i>Current Medical Research and Opinion</i> , 2018, 34, 1803-1807.  | 0.9 | 13        |
| 61 | The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 146-152. | 0.9 | 13        |
| 62 | Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study. <i>European Journal of Neurology</i> , 2019, 26, 363-370.            | 1.7 | 12        |
| 63 | Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. <i>European Journal of Neurology</i> , 2021, 28, 1299-1307.  | 1.7 | 12        |
| 64 | Multiple attack study on the available triptans in Italy versus placebo. <i>European Journal of Neurology</i> , 2005, 12, 557-563.   | 1.7 | 11        |
| 65 | Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 245-249.                    | 1.4 | 11        |
| 66 | Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 755-766.   | 1.4 | 11        |
| 67 | Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses. <i>Neurologist</i> , 2015, 19, 153-154.   | 0.4 | 10        |
| 68 | Diagnostics of anti-MAG antibody polyneuropathy. <i>Neurological Sciences</i> , 2017, 38, 249-252.   | 0.9 | 9         |
| 69 | Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry. <i>Journal of the Neurological Sciences</i> , 2021, 430, 118067.   | 0.3 | 9         |
| 70 | Detection of Neurofilament Light Chain with Label-Free Electrolyte-Gated Organic Field-Effect Transistors. <i>Advanced Materials Interfaces</i> , 2022, 9, .   | 1.9 | 9         |
| 71 | Semiautomated segmentation of the human spine based on echoplanar images. <i>Magnetic Resonance Imaging</i> , 2011, 29, 1429-1436.   | 1.0 | 8         |
| 72 | Diagnostics of dysimmune peripheral neuropathies. <i>Neurological Sciences</i> , 2017, 38, 243-247.  | 0.9 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Microglia activation: a role for mitochondrial DNA?. <i>Neural Regeneration Research</i> , 2021, 16, 2393.  | 1.6 | 8         |
| 74 | The effectiveness of natalizumab vs fingolimod – A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 53, 103012.  | 0.9 | 8         |
| 75 | Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts. <i>CNS Drugs</i> , 2021, 35, 1217-1232.                            | 2.7 | 8         |
| 76 | Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker. <i>Neurological Sciences</i> , 2013, 34, 769-771. | 0.9 | 7         |
| 77 | Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score. <i>Multiple Sclerosis Journal</i> , 2021, 27, 695-705.  | 1.4 | 7         |
| 78 | Recurrent Varicella following Steroids and Fingolimod in a Multiple Sclerosis Patient. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1059-1061.   | 2.1 | 6         |
| 79 | Severe anemia in a patient with multiple sclerosis treated with natalizumab. <i>Neurology</i> , 2014, 83, 374-375.  | 1.5 | 6         |
| 80 | Treatment response score to glatiramer acetate or interferon beta-1a. <i>Neurology</i> , 2020, 96, 10.1212/WNL.0000000000010991.  | 1.5 | 6         |
| 81 | Evidence of different spinal pathways for the warmth evoked potentials. <i>Clinical Neurophysiology</i> , 2011, 122, 2469-2474.   | 0.7 | 5         |
| 82 | False positive absent somatosensory evoked potentials in cardiac arrest with therapeutic hypothermia. <i>Resuscitation</i> , 2014, 85, e183-e184.   | 1.3 | 5         |
| 83 | Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy. <i>Neuroepidemiology</i> , 2021, 55, 224-231.   | 1.1 | 4         |
| 84 | Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration. <i>Journal of Neurology</i> , 2022, 269, 1463-1469.                                  | 1.8 | 4         |
| 85 | Inter-center agreement in the interpretation of oligoclonal bands. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e91-e94.   | 1.4 | 4         |
| 86 | Antiepileptic drugs in the preventive treatment of migraine in children and adolescents. <i>Drug Development Research</i> , 2007, 68, 355-359.  | 1.4 | 3         |
| 87 | Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome. <i>Journal of NeuroVirology</i> , 2017, 23, 329-334.       | 1.0 | 3         |
| 88 | Abnormal Circadian Modification of A $\alpha$ -Fiber Pathway Excitability in Idiopathic Restless Legs Syndrome. <i>Pain Research and Management</i> , 2019, 2019, 1-8.  | 0.7 | 3         |
| 89 | A voxel-based lesion symptom mapping analysis of chronic pain in multiple sclerosis. <i>Neurological Sciences</i> , 2021, 42, 1941-1947.  | 0.9 | 3         |
| 90 | Determinants of therapeutic lag in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1838-1851.   | 1.4 | 3         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Modulation of Tregs and iNKT by Fingolimod in Multiple Sclerosis Patients. <i>Cells</i> , 2021, 10, 3324.   | 1.8 | 3         |
| 92  | Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom. <i>Pharmacoeconomics</i> , 2022, 40, 323-339. | 1.7 | 3         |
| 93  | Letter to Editor: Carpal tunnel syndrome due to an atypical deep soft tissue leiomyoma: The risk of misdiagnosis and mismanagement. <i>World Journal of Surgical Oncology</i> , 2008, 6, 22.  | 0.8 | 2         |
| 94  | Paroxysmal ventricular tachycardia and pure right insular stroke. <i>Journal of Cardiovascular Medicine</i> , 2012, 13, 842-843.  | 0.6 | 2         |
| 95  | Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1550-1550.  | 1.4 | 2         |
| 96  | Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.  | 0.9 | 2         |
| 97  | Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. <i>Multiple Sclerosis Journal</i> , 2022, , 135245852210845.   | 1.4 | 2         |
| 98  | Inter-Laboratory Concordance of Cerebrospinal Fluid and Serum Kappa Free Light Chain Measurements. <i>Biomolecules</i> , 2022, 12, 677.   | 1.8 | 2         |
| 99  | Antiepileptic drugs in the treatment of headache: neuroprotective effect or something else?. <i>Journal of Headache and Pain</i> , 2004, 5, s117-s120.  | 2.5 | 1         |
| 100 | Left thalamomegaly in a patient with partial epilepsy. <i>Clinical Neurology and Neurosurgery</i> , 2008, 110, 298-301.   | 0.6 | 1         |
| 101 | Acute hemichorea as unusual first multiple sclerosis presentation. <i>Neurology: Clinical Practice</i> , 2017, 7, e9-e11.   | 0.8 | 1         |
| 102 | Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 269-277.   | 1.7 | 1         |
| 103 | A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117430.   | 0.3 | 1         |
| 104 | Confirmed disability progression as a marker of permanent disability in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, , .  | 1.7 | 1         |
| 105 | PO.12 INTESTINAL PERMEABILITY IN MIGRAINEURS. <i>Digestive and Liver Disease</i> , 2008, 40, S175.  | 0.4 | 0         |
| 106 | Isolated progressive cognitive impairment and depression in a patient with neuroradiological features suggestive of multiple sclerosis. <i>Neurological Sciences</i> , 2011, 32, 695-697.   | 0.9 | 0         |
| 107 | Cerebrospinal fluid free light chains determination in oligoclonal bands negative patients with suspected multiple sclerosis. <i>Clinica Chimica Acta</i> , 2019, 493, S616-S617.   | 0.5 | 0         |
| 108 | Informing MS patients on treatment options: a consensus on the process of consent taking. <i>Neurological Sciences</i> , 2020, 41, 2249-2253.   | 0.9 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 109 | Brain volume measures in adults with MOG-antibody associated disease: A longitudinal multicentre study. <i>Journal of the Neurological Sciences</i> , 2021, 429, 118108. | 0.3 | 0         |
| 110 | Diagnostic features of initial demyelinating events associated with serum MOG-IgG. <i>Journal of Neuroimmunology</i> , 2020, 344, 577260.                                | 1.1 | 0         |